# An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

> **NCT04339829** · PHASE2 · UNKNOWN · sponsor: **Guangdong Association of Clinical Trials** · enrollment: 50 (estimated)

## Conditions studied

- Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

## Interventions

- **DRUG:** Dacomitinib

## Key facts

- **NCT ID:** NCT04339829
- **Lead sponsor:** Guangdong Association of Clinical Trials
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2022-07-01
- **Final completion:** 2023-08-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04339829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04339829, "An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04339829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*